Table 1.
Patient and donor clinical data. Data is expressed as mean ± standard deviation or in percentage. HCV: hepatitis C virus. 12 M: 12 months after liver transplantation. Alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT).
| F0 (n = 81) | F1 (n = 53) | F2 (n = 41) | F3 (n = 22) | F4 (n = 6) | |
|---|---|---|---|---|---|
| Age (years) | 64.8 ± 8.5 | 65.6 ± 7.5 | 64.2 ± 9.1 | 68.4 ± 7.3 | 67.5 ± 8.9 |
| Donor age | 42.7 ± 16.7 | 46.9 ± 18.2 | 50.3 ± 18.5 | 45.9 ± 17.5 | 48.8 ± 15.5 |
| Male (%) | 67.9 | 60 | 68.3 | 54.5 | 33.3 |
| Donor: male (%) | 58.8 | 72 | 68.3 | 81.8 | 83.3 |
| Aetiology (cases HCV + alcohol) | 20 | 13 | 10 | 5 | 1 |
| Hepatocellular carcinoma (No.) | 47 | 27 | 22 | 15 | 4 |
| Ischemia time (min.) | 385 | 342 | 399 | 285 | 259 |
| Genotype HCV 1a:1b:2:3:4 (%) | 9:84:1:4:1 | 10:81:0:8:0 | 8:79:3:8:3 | 5:90:0:5:0 | 0:100:0:0 |
| Allograft rejection (No.) | 18 | 18 | 11 | 4 | 0 |
| ALT 12 M (U/l) | 113 ± 120 | 144 ± 194 | 148 ± 111 | 173 ± 132 | 183 ± 68 |
| GGT 12 M (U/l) | 234 ± 400 | 313 ± 518 | 365 ± 404 | 651 ± 1013 | 970 ± 863 |
| Alkaline phosphatase 12 M (mg/dl) | 391 ± 407 | 370 ± 271 | 466 ± 611 | 683 ± 590 | 784 ± 234 |
| Bilirubin 12 M | 1.2 ± 1.1 | 1.1 ± 0.7 | 1.5 ± 1.1 | 2.0 ± 1.8 | 3.2 ± 3.3 |
| Viral load (Log) 12 M | 6.2 ± 0.7 | 6.1 ± 0.7 | 6.3 ± 0.6 | 6.0 ± 1.4 | 6.5 ± 0.3 |
| Diabetes type II 12 M (% cases) | 50.6 | 47.2 | 73.2 | 68.2 | 83.3 |
| Arterial hypertension 12 M (% cases) | 39.5 | 35.8 | 46.3 | 50.0 | 83.3 |